Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A study assessing the combination of Dacomitinib and Crizotinib in patients with previously treated metastatic HER2-negative breast cancer

Next Previous
Search
Trial Profile

A study assessing the combination of Dacomitinib and Crizotinib in patients with previously treated metastatic HER2-negative breast cancer

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 03 Feb 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Crizotinib (Primary) ; Dacomitinib (Primary)
  • Indications Advanced breast cancer; HER2 negative breast cancer
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 03 Feb 2021 New trial record
  • 27 Jan 2021 According to a Celcuity media release, the company will obtain interim results 12 to 15 months after the protocol is activated and final results 12-15 months later. Celcuity expects enrollment to begin in the second quarter of 2021.
  • 27 Jan 2021 According to a Celcuity media release, Sarah Cannon Research Institute will serve as the sponsor and Erika Hamilton, MD, will serve as the principal investigator of this study.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top